A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)

Exclusion Criteria

• •Pregnant or lactating women
• •ECOG ≥ 2
• •Have been treated with capecitabine
• •Evidence of CNS metastasis
• •History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast cancer
• •Abnormal laboratory values: hemoglobin \< 10.0 g/dl, absolute neutrophil count \< 1.5×10\^9/L, platelet count \< 100×10\^9/L, serum creatinine \> upper limit of normal (ULN), serum bilirubin \> ULN, ALT and AST \> 5×ULN, AKP \> 5×ULN
• •Serious uncontrolled intercurrent infection
• •Life expectancy of less than 3 months